The new detection equipment can produce results within 4 minutes, and the research progresses in one week of infection with two mutant strains or genetic recombination at the same time

If the epidemic prevention restrictions are relaxed, it may lead to 2 million new deaths in a year

If epidemic prevention restrictions are relaxed, it may lead to 2 million new deaths in one year If epidemic prevention restrictions are relaxed, it may lead to 2 million new deaths in one year

Source: China CDC Weekly

Source: China CDC Weekly Source: China CDC Weekly

A recent study published in the "China CDC Weekly" (China CDC Weekly) shows that for a country like China, which is basically free of the epidemic, if the epidemic prevention restrictions are relaxed, there may be more than 2.
34% of the epidemic in a year.
million infections and 2 million deaths
.

The researchers constructed a cross-regional mobility dynamics model to assess the relationship between population mobility and the COVID-19 pandemic
.

Using studies in the UK and Chile to calculate the baseline efficacy of the current vaccine, the results showed baseline efficacy against infection, symptomatic disease and death were 30%, 68.

Simultaneous infection of two new coronavirus variants or genetic recombination

Simultaneous infection of two new coronavirus variants or genetic recombination Simultaneous infection of two new coronavirus variants or genetic recombination

Source: Emerging Microbes & Infections

Source: Emerging Microbes & Infections Source: Emerging Microbes & Infections

Recently, a study published in Emerging Microbes & Infections reported that genetic recombination events between different mutants occurred in patients with new coronary pneumonia infected with two new coronavirus mutants
.

The researchers emphasized that co-infection and recombination events may not be uncommon, and other recent studies have reported co-infection and recombination events between different new coronavirus variants.
Non-medical interventions should be continuously implemented, and individuals infected with different virus variants should be isolated separately.
patients to prevent the emergence of new recombinant viruses
.

The results of the world's first "intentional human infection with the new crown" test announced

The results of the world's first "intentional human infection with the new crown" test results announced

Source: Research Square

Source: Research Square Source: Research Square

On February 1, a study published in the preprint Research Square selected a low-risk healthy young population, deliberately infected them with the new coronavirus, and accurately measured the virus dynamics, human immune response, and transmission dynamics after infection with the new coronavirus.
, infection,
etc.

Of the total of 36 people, 18 were confirmed to be infected by PCR testing, that is, 50% of the volunteers were infected with the new coronavirus
.

The infection rate in the trial reached the target infection rate of 50%-70%, and the model was shown to have a higher exposure rate than natural infection

The new coronavirus and human consensus sequence is an important pathogenic factor for the new crown

The consensus sequence between the new coronavirus and humans is an important pathogenic factor for the new coronavirus The consensus sequence between the new coronavirus and humans is an important pathogenic factor for the new coronavirus

Source: EbioMedicine

Source: EbioMedicine Source: EbioMedicine

On February 3, in a paper published in EbioMedicine, researchers found through sequence similarity analysis that there were 5 sequences in the new coronavirus genome that were identical to the human genome, named HIS, and these sequences were found in 159,258 new coronavirus genomes.
Moderately conservative
.

Bioinformatics analysis found that the new coronavirus HIS is located at the human genome enhancer site and may be a virus-derived miRNA
.

In addition, 6 other human coronaviruses, including SARS, all have short sequences that are exactly the same as the human genome

Alzheimer's-like features appear in the brains of severely ill COVID-19 patients

Alzheimer's-like features appear in the brains of patients who died of new coronary disease

Source: Alzheimer's & Dementia

Source: Alzheimer's & Dementia Source: Alzheimer's & Dementia

On February 3, a study published in "Alzheimer's & Dementia" (Alzheimer's & Dementia) found abnormal changes in the brains of severe deaths from new coronary pneumonia: abnormal amounts of tau protein and tau protein accumulated in brain cells.
Beta-amyloid plaques, which are typical of Alzheimer's disease
.

Researchers studying the brains of 10 people who died from Covid-19 found defects in the ryanodine receptors, a protein that controls the entry of calcium into brain cells
.

In Alzheimer's patients, defective ryanodine receptors are associated with the accumulation of a type of tau called neurofibrillary tangles

New ultra-sensitive new crown detection device can produce results in 4 minutes

The new ultra-high-sensitivity new crown detection device can produce results in 4 minutes The new ultra-high-sensitivity new crown detection device can produce results in 4 minutes

Source: Nature Biomedical Engineering

Source: Nature Biomedical Engineering Source: Nature Biomedical Engineering

A study published in Nature Biomedical Engineering on February 7 demonstrates a molecular electromechanical system consisting of an aptamer probe bound to a flexible single-stranded DNA cantilever and self-contained.
Assembled rigid tetrahedral double-stranded DNA structures are linked for ultrasensitive and specific detection of proteins, small molecules, ions, and nucleic acids in biological fluids
.

Installed an electromechanical biosensor for SARS-CoV-2 detection into an integrated portable prototype device and showed that it detected viral RNA in less than 4 minutes in all nasopharyngeal samples from 33 Covid-19 patients, and in None of the 54 negative controls were detected and no RNA extraction or nucleic acid amplification was required
.

The risk of major adverse cardiovascular events in patients with new crown infection is 55% higher than ordinary people

The risk of major adverse cardiovascular events in patients with new crown infection is 55% higher than that of ordinary people The risk of major adverse cardiovascular events in patients with new crown infection is 55% higher than ordinary people

Source: Nature Medicine

Source: Nature Medicine Source: Nature Medicine

A study published in Nature Medicine on February 7 found that people with Covid-19 had an increased risk of cardiovascular complications in the first month to a year after infection
.

The researchers analyzed the data including women and adults of all ages and races
.

A year-long follow-up of these people's heart health found that heart disease rates were 4 percent higher than those who did not contract Covid-19

Symptomatic recoveries from COVID-19 have neutralizing antibody response times of up to 480 days

Neutralizing antibody response time of symptomatic recoveries from new crown infection can be up to 480 days Neutralizing antibody response time of symptomatic recovered patients of new crown infection can take up to 480 days

Source: Nature Microbiology

Source: Nature Microbiology Source: Nature Microbiology

A study published in Nature Microbiology on February 7 measured 411 consecutive samples collected from 214 COVID-19 survivors from 1 to 480 days (dao) after disease onset or laboratory confirmation.
nAb titers of plasma samples
.

The results showed that anti-RBD IgG and MN titers peaked at ~120 dao and subsequently declined, with significantly lower nAb responses found in 91.
67% of convalescent patients
.

However, anti-RBD IgG and MN titers of most convalescent patients were still detectable at 400-480 dao; at 330-480 dao, they were found in 14.

Combination of antiviral drugs can effectively deal with the new crown

Combination of antiviral drugs can effectively deal with the new crown Antiviral drug combination can effectively deal with the new crown

Source: Nature

Source: Nature Source: Nature

On February 7, a study published in "Nature" pointed out that the nucleotide drugs Brequinar and remdesivir or new crown oral drugs are currently undergoing clinical trials against the new coronavirus.

The researchers hypothesized that combining buquina with nucleoside analogs could "synergize" to produce a more potent antiviral effect, and tested them in lung cells and mice and found that these combinations were very effective against multiple new coronavirus strains.

The protective effect of the trivalent nasal spray of the new crown vaccine is broader and longer

The protective effect of the trivalent nasal spray Covid-19 vaccine is broader and longer-lasting

Source: Cell

Source: Cell Source: Cell

In a work published in Cell on February 8, researchers evaluated a nasally administered trivalent adenovirus SARS-CoV-2 vaccine

Studies have shown that the vaccine can effectively avoid immune escape caused by mutations in the new coronavirus; it is better than intramuscular vaccination in terms of local and systemic neutralizing antibodies, T-cell immune responses, and improving mucosal innate immunity; in addition, clinical indicators in animal models.

Analysis of the spike protein structure of the Omicron variant provides new ideas for the design and development of broad-spectrum anti-COVID-19 antibodies

Analyzing the structure of the spike protein of the Omicron variant provides new ideas for the design and development of broad-spectrum anti-COVID-19 antibodies

Source: Science

Source: Science Source: Science

On February 8, a study published in "Science" analyzed the high-resolution cryo-electron microscope structure of the Omicron variant spike protein that binds to the human receptor ACE2 and the broad-spectrum anti-COVID-19 antibody JMB2002 complex, respectively.
, expounded the molecular mechanism of the rapid spread and immune escape of the Omicron variant, and revealed the new mechanism of action of the therapeutic antibody JMB2002, providing new ideas for the design and development of broad-spectrum anti-COVID-19 antibodies
.

leave a message here